Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial.
Journal of the Formosan Medical Association = Taiwan yi zhi · 2015-03-17 · Randomised trial
Abstract
BACKGROUND/PURPOSE: To compare the efficacy and safety profile between intramuscular (IM) olanzapine and IM haloperidol plus IM lorazepam in acute schizophrenic patients with moderate to severe agitation. METHODS: This was a prospective, randomized, open-label study. Acutely agitated patients with schizophrenia or schizoaffective disorder (n = 67) were randomized to receive 10 mg IM olanzapine (n = 37) or 5 mg IM haloperidol plus 2 mg IM lorazepam (n = 30). Agitation was measured with Positive and Negative Syndrome Scale Excited Component (PANSS-EC) and Agitation-Calmness Evaluation Scale (ACES) during the first 2 hours and at 24 hours after the first injection. Safety was assessed using the Simpson-Angus Scale and Barnes Akathisia Rating Scale and by recording adverse events at 24 hours following the first injection. The Clinical Global Impression-Severity scale was also rated. RESULTS: The PANSS-EC scores decreased significantly at 2 hours after the first injection in both groups (olanzapine: -10.2, p < 0.001; haloperidol + lorazepam: -9.9, p < 0.001). Haloperidol plus lorazepam was not inferior to olanzapine in reducing agitation at 2 hours. There were no significant differences in PANSS-EC or ACES scores between the two groups within 2 hours following the first injection. The frequencies of adverse events and changes in Clinical Global Impression-Severity, Simpson-Angus Scale, and Barnes Akathisia Rating Scale scores from baseline to 24 hours showed no significant differences between the groups. CONCLUSION: The findings suggest that IM haloperidol (5 mg) plus lorazepam (2 mg) is not inferior to IM olanzapine (10 mg) in the treatment of acute schizophrenic patients with moderate to severe agitation (ClinialTrials.gov identifier number NCT00797277).
Abstract © the authors or publisher, via PubMed. Reuse and removal
Tags
Antipsychotics · Other benzodiazepines & Z-drugs · Sedatives & anxiolytics
Related articles
- Treatment of Agitation With Lorazepam in Clinical Practice: A Systematic Review. (Front Psychiatry, 2021)
- Oral Medication for Agitation of Psychiatric Origin: A Scoping Review of Randomized Controlled Trials. (J Emerg Med, 2017)
- Pharmacological treatment of acute agitation associated with psychotic and bipolar disorder: a systematic review and meta-analysis. (Hum Psychopharmacol, 2016)
- Randomized Double-blind Trial of Intramuscular Droperidol, Ziprasidone, and Lorazepam for Acute Undifferentiated Agitation in the Emergency Department. (Acad Emerg Med, 2021)
- Efficacy of ketamine for initial control of acute agitation in the emergency department: A randomized study. (Am J Emerg Med, 2021)
- Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole. (J Clin Psychopharmacol, 2007)